Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Hypertension is a leading global cause of premature death and disease burden, primarily linked to cardiovascular disease.
• Achieving target blood pressure (BP) and cholesterol levels remains a challenge in both primary and secondary cardiovascular disease prevention.
• Fixed-dose combination pills, or polypills, are proposed to complement existing therapies for cardiovascular disease prevention.

Purpose of the Study:

• To review the potential role of fixed-dose combination therapy in hypertension management.
• To outline the advantages and disadvantages of combination therapy for cardiovascular disease prevention.
• To summarize current and planned polypill trials and discuss implementation prerequisites.

Main Methods:

• Literature review focusing on fixed-dose combination therapy for hypertension.
• Analysis of the rationale, pros, and cons of combination therapy.
• Summary of existing and upcoming cardiovascular polypill clinical trials.

Main Results:

• Fixed-dose combination therapy, particularly the cardiovascular polypill, presents a complementary strategy for improving cardiovascular disease prevention.
• Challenges in achieving BP and cholesterol targets highlight the need for novel therapeutic approaches.
• Several polypill trials are underway, with specific prerequisites for successful implementation.

Conclusions:

• The cardiovascular polypill strategy holds significant potential for enhancing cardiovascular disease prevention by improving treatment adherence and goal achievement.
• Further research and careful implementation are necessary to realize the full benefits of polypill therapy in managing hypertension and reducing cardiovascular risk.